菲利林和菲利基宁对弹性酶的比较抑制作用:机制和治疗潜力
Wenhui Zhang1, Jinfeng Fu2, Hongliu Yao2
1Department of Neurosurgery, The Second Hospital of Tianjin Medical University, Tianjin, China.
Frontiers in nutrition
|February 27, 2026
概括
福西西亚木质素,菲利林和菲利基宁,抑制弹性酶,这是炎症性疾病中的关键酶. 菲利基宁表现出更强的抑制作用,这表明它对COPD等疾病的潜在治疗应用.
科学领域:
- 生物化学 生物化学
- 药理学 药理学是指药理学的学科.
- 分子生物学分子生物学
背景情况:
- 弹性酶是一种血清蛋白酶,在慢性阻塞性肺病 (COPD) 和全身炎症反应综合征 (SIRS) 等疾病中起着重要作用.
- 向弹性酶活性是管理这些炎症状况的潜在治疗策略.
研究的目的:
- 为了研究菲利林和菲利基宁 (Forsythia物种中的两种主要基素) 对弹性酶活性的抑制作用.
- 阐明抑制的机制,并评估这些化合物作为治疗剂的潜力.
主要方法:
- 进行了酶动力学测试,以确定抑制模式和抑制常量 (Ki).
- 使用光谱技术 (例如,循环二重化) 来分析弹性酶在连接物结合时的形状变化.
- 用分子对接模拟来预测在分子层面上类和弹性酶之间的结合相互作用.
主要成果:
- 菲利林和菲利基宁都显示出对弹性酶的竞争性抑制.
- 与菲利林 (IC50 = 1.5 mmol/L,Ki = 9.7 × 10^-4 mol/L) 相比,菲利基宁表现出更高的抑制活性 (IC50 = 0.5 mmol/L,Ki = 4.0 × 10^-4 mol/L).
- 谱学和对接分析显示,这些类诱导了弹性酶的结构变化,并通过各种力量相互作用,包括键和疏水相互作用.
结论:
- 菲利林和菲利基宁通过竞争机制有效抑制弹性酶.
- 菲利基宁表现出更强的抑制潜力,可能是由于其化学结构.
- 这些发现提供了有价值的机理性见解,并支持Forsythia lignans作为弹性酶介导疾病的新型治疗剂的潜力.
相关概念视频
Enzyme Inhibition
93.4K
Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
93.4K
Protein Kinases and Phosphatases
15.3K
Proteins undergo chemical modifications that trigger changes in the charge, structure, and conformation of the proteins. Phosphorylation, acetylation, glycosylation, nitrosylation, ubiquitination, lipidation, methylation, and proteolysis are various protein modifications that regulate protein activity. Such modifications are usually enzyme-driven.
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
15.3K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
552
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
552


